Vitiligo Clinical Trial
Official title:
Pilot Trial to Determine the Efficacy of Secukinumab in Active Non-segmental Vitiligo
Verified date | February 2023 |
Source | University Hospital, Ghent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vitiligo is an acquired autoimmune skin disorder which leads to cutaneous depigmentations. A lot of progress has been made to unravel the pathophysiology of vitiligo. Several independent studies confirmed the elevated values of IL-17 in the serum of vitiligo patients and higher IL-17 values have been linked to a higher affected body surface area and a longer disease duration. The study will be a pilot trial with secukinumab in patients with active, non-segmental vitiligo. All patients will receive the active compound (= no placebo arm) as the purpose of the study is to investigate the potential efficacy of secukinumab in vitiligo.
Status | Completed |
Enrollment | 8 |
Est. completion date | February 22, 2019 |
Est. primary completion date | December 16, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Moderate to extensive vitiligo 2. Vitiligo patients with active vitiligo. 3. Vitiligo on hands and/or face 4. Fitzpatrick skin type 3-6 5. High impact Exclusion Criteria: 1. Active systemic infections during the 2 weeks prior to baseline (exception: common cold) or any infection that reoccurs on a regular basis. 2. Autoimmune diseases (except thyroid disease) 3. Use of immunosuppressive treatments 4. Pregnancy or breastfeeding 5. Mycobacterium tuberculosis infection as shown by positive Mantoux and/or Quantiferon test 6. Clinical important abnormalities in blood analysis before start 7. Use of any other investigational drug within 4 weeks prior to baseline or within a period of 5 half-lives of the investigational drug, whichever is langer (in order to assess properly the safety of secukinumab) 8. History of hypersensitivity to any of the studied drugs or to drugs of similar chemical classes including latex hypersensitivity 9. Important underlying medical conditions 10. Significant medical problems 11. Serum creatinine level exceeding 2.0 mg/dL (176.8 pmol/L) at screening. 12. Total white blood cell (WBC) count < 2500/pL, platelets < 100 000/pL, neutrophils < 1500/ML or hemoglobin < 8.5 g/dL, at screening. 13. Past medical history record of, or current infection with, human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus prior to baseline. 14. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or noninvasive malignant colon polyps that have been removed). 15. Current severe progressive or uncontrolled disease which in the judgment of the Investigator renders the patient unsuitable for the study or puts the patiƫnt at increased risk (eg, myocardial infarction within 26 weeks prior to baseline). 16. Inability or unwillingness to undergo repeated venipuncture (eg, because of poor tolerability or lack of access to veins). 17. Any medical or psychiatric condition which, in the investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol. 18. History or evidence of ongoing alcohol or drug abuse, within the last 6 months prior to baseline. 19. Plans for administration of live vaccines during the study period or in the 6 weeks prior to baseline. |
Country | Name | City | State |
---|---|---|---|
Belgium | Department of Dermatology, Ghent University Hospital | Gent | Oost-Vlaanderen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent | Novartis |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Repigmentation (percentage of repigmentation) | The efficacy of the treatment will be determined by measuring the diffference in the percentage of the affected body surface area compared to baseline. The percentage of the affected body surface area will be measured by standardized digital pictures using a validated scoring system (Vitiligo Extent Score plus; VESplus). | 9 months | |
Secondary | Stabilisation of disease (percentage of affected body surface area) | The efficacy of the treatment will be determined by measuring the diffference in the percentage of the affected body surface area compared to baseline. The percentage of the affected body surface area will be measured by standardized digital pictures using a validated scoring system (Vitiligo Extent Score plus; VESplus). | 9 months | |
Secondary | Disease impact | Global impact score (0-10), where the higher the score the worse the outcome | 9 months | |
Secondary | Satisfaction with treatment | Global Satisfaction Score, where the higher the score the better the outcome | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |